

**ALEMBIC PHARMACEUTICALS LIMITED**

CIN: L24230GJ2010PLC061123

Regd. Office: Alembic Road, Vadodara - 390 003

Tel: 0265-6637300

Email: apl.investors@alembic.co.in

Website: www.alembicpharmaceuticals.com

**Extract of Statement of Consolidated Unaudited Financial Results for the quarter and nine months period ended 31<sup>st</sup> December, 2023**

(₹ in Crores except per share data)

| Particulars   | Quarter Ended |             | Year Ended |
|---|---------------|-------------|------------|
|   | 31.12.2023    | 31.12.2022  | 31.03.2023 |
|   | (Unaudited)   | (Unaudited) | (Audited)  |
| Total Income from Operations  | 1,630.57      | 1,509.02    | 5,652.62   |
| Net Profit for the period (before Tax, Exceptional and/ or Extraordinary items)   | 184.58        | 154.49      | 354.59     |
| Net Profit for the period before tax (after Exceptional and/ or Extraordinary items)  | 184.58        | 154.49      | 354.59     |
| Net Profit for the period after tax attributable to shareholders of the company (after Exceptional and/ or Extraordinary items) | 180.45        | 121.92      | 341.99     |
| Total Comprehensive Income for the period   | 181.49        | 124.94      | 355.36     |
| Equity Share Capital  | 39.31         | 39.31       | 39.31      |
| Earning Per Share (Face Value of ₹ 2/- each) Basic & Diluted  | 9.18          | 6.20        | 17.40      |
| Research and Development Expenses   | 114.48        | 156.89      | 721.84     |

**Notes:**

| 1. Standalone details             | Quarter Ended |             | Year Ended |
|-----------------------------------|---------------|-------------|------------|
|                                   | 31.12.2023    | 31.12.2022  | 31.03.2023 |
|                                   | (Unaudited)   | (Unaudited) | (Audited)  |
| Income from Operations            | 1,588.39      | 1,310.21    | 5,149.00   |
| Profit Before Tax                 | 256.70        | 144.31      | 345.93     |
| Profit After Tax                  | 233.24        | 119.13      | 346.73     |
| Research and Development Expenses | 113.75        | 149.02      | 699.39     |

2. The above is an extract of the detailed format of the Unaudited Financial Results filed with the Stock Exchanges. The detailed Financial Results are available on the Company's website at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) and the Stock Exchange's website at [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com)

For Alembic Pharmaceuticals Limited  
Sd/-

Place : Vadodara

Date : 5<sup>th</sup> February, 2024

Chirayu Amin  
Chairman and CEO